Delcath Systems Inc.
600 Fifth Avenue
23rd Floor
New York,
NY 10020
United States - Map
Phone: 212-489-2100
Fax: 212-489-2102
Web Site: http://www.delcath.com
| Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patientÂ’s general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver. The Delcath PHP System kit includes an arterial infusion catheter, a multi-passageway/double balloon catheter, a blood tubing/extracorporeal filtration circuit, two activated carbon hemoperfusion filters, a return catheter/a thin-walled blood sheath, and a series of introducers and related accessories to properly place the catheters. The company also conducts Phase II clinical trials to test the Delcath PHP System with the drug melphalan against liver cancer/hepatocellular tumors, neuroendocrine and adenocarcinoma tumors that have spread to the liver, and melanomas metastatic to the liver that have received prior regional treatment. It has a collaboration with the National Cancer Institute to develop and evaluate the Delcath PHP System device to deliver high-dose melphalan to patients, and to evaluate the use of additional chemotherapy agents with the Delcath PHP System. Delcath Systems, Inc. was founded in 1988 and is based in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Eamonn P. Hobbs , 51
Chief Exec. Officer, Pres, Director, Member of Audit Committee and Member of Nominating & Corp. Governance Committee |
$
6.00K | N/A | Mr. Richard Taney J.D.,
Exec. Director |
$
456.00K | N/A | Mr. Jason Rifkin Esq., 31
Sr. VP of Clinical Operations and Sec. |
$
150.00K | N/A | Mr. David Alan McDonald , 48
Chief Financial Officer |
N/A
| N/A | Mr. Armand Frigon ,
VP of Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.14% Nasdaq 
0.48 (10.88%) 
Profile
